Curated News
By: NewsRamp Editorial Staff
August 14, 2025

BioCorRx Reports 4,306% Revenue Surge with Breakthrough Addiction Treatments

Reddit Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • BioCorRx Inc. leverages its acquisition of LUCEMYRA to achieve a 4,306% revenue increase, positioning it as a leader in non-opioid addiction treatments.
  • BioCorRx Inc. reported a 4,306% revenue increase to $178K in Q2 2025, following the strategic acquisition of LUCEMYRA, enhancing its treatment portfolio for substance abuse.
  • BioCorRx Inc.'s advancements in addiction treatment, including LUCEMYRA and BICX104, offer hope for millions affected by substance abuse, aiming to reduce global health crises.
  • Discover how BioCorRx Inc.'s LUCEMYRA, the first FDA-approved non-opioid for opioid withdrawal, is revolutionizing addiction treatment with a 4,306% revenue surge in Q2 2025.

Impact - Why it Matters

The advancements and financial growth reported by BioCorRx Inc. are not just numbers; they represent hope for millions affected by substance abuse and related disorders. The acquisition of LUCEMYRA® and the development of BICX104 could revolutionize treatment options for opioid withdrawal and methamphetamine use disorder, addressing critical gaps in current healthcare solutions. This news matters because it highlights the potential for significant improvements in public health, offering new avenues for treatment and recovery for individuals and families grappling with addiction.

Summary

BioCorRx Inc. (OTCQB: BICX), a leader in innovative treatment programs for substance abuse, has reported a staggering 4,306% increase in revenue to $178K for the second quarter of 2025, following the strategic acquisition of LUCEMYRA® (lofexidine), the first FDA-approved non-opioid treatment for opioid withdrawal symptoms. CEO Lourdes Felix highlighted the acquisition's immediate impact on revenue growth and a significant reduction in net loss, underscoring the company's strengthened financial position. Additionally, BioCorRx Pharmaceuticals Inc. is advancing its research on BICX104, a potential breakthrough for methamphetamine use disorder (MUD), supported by a grant from the National Institute on Drug Abuse. With no current medications specifically approved for MUD, this development represents a critical step forward in addressing a major public health challenge.

The company's efforts extend beyond opioid and methamphetamine use disorders, with ongoing initiatives in obesity treatment through its UnCraveRx® Weight Loss Program. BioCorRx's comprehensive approach to addiction and related disorders, combining medication-assisted treatments with behavioral therapy and peer support, positions it as a pivotal player in tackling some of the most pressing health issues today. For more details on BioCorRx's innovative solutions and financial performance, visit https://ir.biocorrx.com/.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BioCorRx Reports 4,306% Revenue Surge with Breakthrough Addiction Treatments

blockchain registration record for this content.